Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760
Debt
Debt-to-Equity Ratio1.30
Current Ratio5.90
Quick Ratio5.90
Price-To-Earnings
Trailing P/E Ratio-9.33
Forward P/E Ratio-7.29
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book14.88
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-138.96%
Return on Assets-48.63%
Miscellaneous
Employees6
Outstanding Shares30,110,000
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio (NASDAQ:SPHS) announced its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.02. View Sophiris Bio's Earnings History.
What price target have analysts set for SPHS?
2 Wall Street analysts have issued twelve-month price targets for Sophiris Bio's stock. Their forecasts range from $6.00 to $8.00. On average, they expect Sophiris Bio's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Sophiris Bio.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Depomed (DEPO), Sinovac Biotech (SVA), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Synergy Pharmaceuticals (SGYP), GTX (GTXI), Syros Pharmaceuticals (SYRS), Bellicum Pharmaceuticals (BLCM), Dermira (DERM), Achillion Pharmaceuticals (ACHN), Axovant Sciences (AXON), American Brivision (Holding) (ABVC), Savara (SVRA), Albireo Pharma (ALBO) and Tyme Technologies (TYME).
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Mr. Randall E. Woods, Pres, CEO & Director (Age 66)
- Mr. Peter T. Slover CPA, Chief Financial Officer (Age 43)
- Dr. Allison J. Hulme Ph.D., COO, Head of R&D and Director (Age 55)
- Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
- Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)
Has Sophiris Bio been receiving favorable news coverage?
News stories about SPHS stock have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sophiris Bio earned a daily sentiment score of 0.12 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 44.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Sophiris Bio's major shareholders?
Which major investors are selling Sophiris Bio stock?
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $3.72.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $113.52 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
